CLL Treatment: 100% Response with VenR Retreatment
Patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) have reason for optimism: a combination of venetoclax and rituximab (VenR) has demonstrated a 100% response rate … Read more